<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369161">
  <stage>Registered</stage>
  <submitdate>20/08/2015</submitdate>
  <approvaldate>8/09/2015</approvaldate>
  <actrnumber>ACTRN12615000938505</actrnumber>
  <trial_identification>
    <studytitle>The NACSTOP trial: Investigation of the early cessation of N-acetylcysteine after paracetamol overdose.</studytitle>
    <scientifictitle>Investigation of the early cessation of N-acetylcysteine versus standard care on liver injury after paracetamol overdose.</scientifictitle>
    <utrn>U1111-1173-4474</utrn>
    <trialacronym>NACSTOP</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Paracetamol overdose</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Suicide</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Poisoning</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients with normal ALT and AST (within lab reference range) and paracetamol&lt;132 micro mol/L, will be allocated to either intervention or control treatment.

200mg/kg of NAC intravenously over 4 hours, then 50mg/kg NAC over 8 hours intravenously then change to 1 litre of intravenous Compound serum Lactate over 8 hours if study criteria met at 12 hours (alanine transaminase and AST less than the upper limit of the lab reference range, paracetamol &lt;132 micro mol/L) in intervention group. Bloods will then be repeated again at 20 hrs post initiation of NAC. A normal alanine transaminase indicates no sign of liver toxicity and low paracetamol concentration at less than therapeutic dose of paracetamol in the blood.

Lab reference range for ALT, AST will vary from institution but the higher end of the range is 50 IU/L.

Strategies to monitor medication adherence include observation in hospital of administration by medical and nursing staff, and computer logging of drug administration by nursing staff.</interventions>
    <comparator>200mg/kg of NAC intravenously over 4 hours and 100mg NAC intravenously over 16 hours. Normal ALT and AST and paracetamol concentrations &lt;132 micromol/L at 12 hours of NAC will be included in the control treatment group.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum assay of alanine transaminase (ALT). ALT Doubling and ALT &gt; 100 IU/L will be taken as hepatic injury.</outcome>
      <timepoint>20 hrs after initiation of NAC</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hepatotoxicity defined as ALT &gt;1000 IU/L measured by serum assay</outcome>
      <timepoint>20 hrs after NAC initiated</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay will be assessed by review of hospital records</outcome>
      <timepoint>This will be assessed from time of triage to discharge from hospital.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Single or staggered paracetamol overdose
</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Not mentally competant
ALT or AST &gt; lab reference range and/or paracetamol &gt; 132 micromol/L at 12 hours post NAC initiation. 
Participants will be enrolled prior to the blood tests at 12hrs post NAC treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Casey Hospital - Berwick</hospital>
    <hospital>Dandenong Hospital - Dandenong</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Blacktown Hospital - Blacktown</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Monash Health</primarysponsorname>
    <primarysponsoraddress>135 David St, Dandenong 3175, VIC</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Monash Health</fundingname>
      <fundingaddress>135 David St, Dandenong 3175, VIC
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Austin Health</fundingname>
      <fundingaddress>145 Studley Road, Heidelberg 3084, VIC</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Austin Health</sponsorname>
      <sponsoraddress>145 Studley Road, Heidelberg 3084, VIC</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to investigate whether ceasing the use of antidote (NAC) in patients presenting early with paracetamol overdose in a low risk population is feasible and safe.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash HREC</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/01/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>26/08/2015</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Anselm Wong</name>
      <address>145 Studley Road, Heidelberg VIC 3084
Austin Hospital Emergency Department</address>
      <phone>+613 94964509</phone>
      <fax />
      <email>anselm.wong@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anselm Wong</name>
      <address>145 Studley Road, Heidelberg VIC 3084
Austin Hospital Emergency Department</address>
      <phone>+613 9496 4509</phone>
      <fax />
      <email>anselm.wong@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anselm Wong</name>
      <address>145 Studley Road, Heidelberg VIC 3084
Austin Hospital Emergency Department</address>
      <phone>+613 9496 4509</phone>
      <fax />
      <email>anselm.wong@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>